nodes	percent_of_prediction	percent_of_DWPC	metapath
Amiloride—PLAU—pancreatic cancer	0.773	1	CbGaD
Amiloride—PLAU—islet of Langerhans—pancreatic cancer	0.00279	0.146	CbGeAlD
Amiloride—SCNN1A—islet of Langerhans—pancreatic cancer	0.00244	0.128	CbGeAlD
Amiloride—SLC9A1—pancreas—pancreatic cancer	0.00207	0.108	CbGeAlD
Amiloride—PLAU—pancreas—pancreatic cancer	0.00196	0.103	CbGeAlD
Amiloride—AOC1—digestive system—pancreatic cancer	0.00185	0.0965	CbGeAlD
Amiloride—SLC9A1—digestive system—pancreatic cancer	0.00177	0.0925	CbGeAlD
Amiloride—SCNN1A—pancreas—pancreatic cancer	0.00172	0.0899	CbGeAlD
Amiloride—PLAU—digestive system—pancreatic cancer	0.00168	0.0876	CbGeAlD
Amiloride—SCNN1A—digestive system—pancreatic cancer	0.00147	0.0768	CbGeAlD
Amiloride—SLC22A2—digestive system—pancreatic cancer	0.000792	0.0415	CbGeAlD
Amiloride—SLC22A4—digestive system—pancreatic cancer	0.000588	0.0308	CbGeAlD
Amiloride—PLAU—Wnt Signaling Pathway and Pluripotency—CD44—pancreatic cancer	0.000566	0.00552	CbGpPWpGaD
Amiloride—PLAU—Osteopontin-mediated events—MMP9—pancreatic cancer	0.000556	0.00542	CbGpPWpGaD
Amiloride—SLC9A1—Defective B3GAT3 causes JDSSDHD—CD44—pancreatic cancer	0.000555	0.00541	CbGpPWpGaD
Amiloride—PLAU—Senescence and Autophagy in Cancer—CD44—pancreatic cancer	0.000553	0.00539	CbGpPWpGaD
Amiloride—PLAU—amb2 Integrin signaling—MMP9—pancreatic cancer	0.000543	0.00528	CbGpPWpGaD
Amiloride—PLAU—Validated transcriptional targets of AP1 family members Fra1 and Fra2—CXCL8—pancreatic cancer	0.000534	0.0052	CbGpPWpGaD
Amiloride—SLC9A1—Transmembrane transport of small molecules—SLC29A1—pancreatic cancer	0.000516	0.00502	CbGpPWpGaD
Amiloride—PLAU—Validated transcriptional targets of AP1 family members Fra1 and Fra2—CCND1—pancreatic cancer	0.000498	0.00485	CbGpPWpGaD
Amiloride—PLAU—AP-1 transcription factor network—HIF1A—pancreatic cancer	0.000494	0.00482	CbGpPWpGaD
Amiloride—PLAU—FGF signaling pathway—CDH1—pancreatic cancer	0.000493	0.0048	CbGpPWpGaD
Amiloride—PLAU—Validated transcriptional targets of AP1 family members Fra1 and Fra2—MMP9—pancreatic cancer	0.000483	0.00471	CbGpPWpGaD
Amiloride—SLC22A4—SLC-mediated transmembrane transport—SLC29A1—pancreatic cancer	0.000464	0.00452	CbGpPWpGaD
Amiloride—PLAU—ATF-2 transcription factor network—RB1—pancreatic cancer	0.000461	0.00449	CbGpPWpGaD
Amiloride—SLC9A1—RhoA signaling pathway—PTEN—pancreatic cancer	0.000455	0.00443	CbGpPWpGaD
Amiloride—PLAU—ATF-2 transcription factor network—MMP2—pancreatic cancer	0.000442	0.00431	CbGpPWpGaD
Amiloride—PLAU—Senescence and Autophagy in Cancer—SMAD4—pancreatic cancer	0.000437	0.00425	CbGpPWpGaD
Amiloride—PLAU—Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling—MMP9—pancreatic cancer	0.000436	0.00425	CbGpPWpGaD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—SMAD4—pancreatic cancer	0.000424	0.00413	CbGpPWpGaD
Amiloride—PLAU—amb2 Integrin signaling—TNF—pancreatic cancer	0.000418	0.00407	CbGpPWpGaD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—SOD2—pancreatic cancer	0.000413	0.00402	CbGpPWpGaD
Amiloride—PLAU—Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling—SRC—pancreatic cancer	0.000402	0.00392	CbGpPWpGaD
Amiloride—SLC9A1—ErbB1 downstream signaling—BCL2L1—pancreatic cancer	0.000398	0.00387	CbGpPWpGaD
Amiloride—PLAU—Osteopontin-mediated events—PIK3CA—pancreatic cancer	0.00039	0.0038	CbGpPWpGaD
Amiloride—ASIC2—Transmembrane transport of small molecules—SLC2A2—pancreatic cancer	0.00039	0.0038	CbGpPWpGaD
Amiloride—PLAU—E2F transcription factor network—RB1—pancreatic cancer	0.000389	0.00379	CbGpPWpGaD
Amiloride—SLC22A4—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A2—pancreatic cancer	0.000386	0.00376	CbGpPWpGaD
Amiloride—SLC9A1—Carbohydrate metabolism—SLC2A2—pancreatic cancer	0.000385	0.00375	CbGpPWpGaD
Amiloride—PLAU—Beta3 integrin cell surface interactions—VEGFA—pancreatic cancer	0.000385	0.00375	CbGpPWpGaD
Amiloride—SLC9A1—SLC-mediated transmembrane transport—SLC2A2—pancreatic cancer	0.000383	0.00374	CbGpPWpGaD
Amiloride—SLC9A1—Signaling mediated by p38-alpha and p38-beta—TP53—pancreatic cancer	0.00038	0.0037	CbGpPWpGaD
Amiloride—PLAU—ATF-2 transcription factor network—CXCL8—pancreatic cancer	0.000368	0.00358	CbGpPWpGaD
Amiloride—PLAU—Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling—TGFB1—pancreatic cancer	0.00036	0.0035	CbGpPWpGaD
Amiloride—PLAU—FGF signaling pathway—MMP9—pancreatic cancer	0.000357	0.00348	CbGpPWpGaD
Amiloride—PLAU—AP-1 transcription factor network—CDKN2A—pancreatic cancer	0.000354	0.00344	CbGpPWpGaD
Amiloride—PLAU—Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling—EGFR—pancreatic cancer	0.000353	0.00344	CbGpPWpGaD
Amiloride—SLC9A1—ErbB1 downstream signaling—EGF—pancreatic cancer	0.000345	0.00336	CbGpPWpGaD
Amiloride—PLAU—ATF-2 transcription factor network—CCND1—pancreatic cancer	0.000343	0.00334	CbGpPWpGaD
Amiloride—PLAU—E2F transcription factor network—CDKN2A—pancreatic cancer	0.000342	0.00333	CbGpPWpGaD
Amiloride—PLAU—FGF signaling pathway—SRC—pancreatic cancer	0.000329	0.00321	CbGpPWpGaD
Amiloride—SLC9A1—Endothelins—SRC—pancreatic cancer	0.000323	0.00314	CbGpPWpGaD
Amiloride—PLAU—AP-1 transcription factor network—CXCL8—pancreatic cancer	0.000321	0.00312	CbGpPWpGaD
Amiloride—PLAU—FGF signaling pathway—STAT3—pancreatic cancer	0.000317	0.00309	CbGpPWpGaD
Amiloride—PLAU—Endochondral Ossification—MMP9—pancreatic cancer	0.000312	0.00304	CbGpPWpGaD
Amiloride—PLAU—Wnt Signaling Pathway—CCND1—pancreatic cancer	0.000309	0.00301	CbGpPWpGaD
Amiloride—PLAU—Wnt Signaling Pathway—CTNNB1—pancreatic cancer	0.000306	0.00298	CbGpPWpGaD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—PIK3CG—pancreatic cancer	0.000306	0.00298	CbGpPWpGaD
Amiloride—PLAU—AP-1 transcription factor network—CCND1—pancreatic cancer	0.000299	0.00291	CbGpPWpGaD
Amiloride—SLC9A1—Carbohydrate metabolism—CD44—pancreatic cancer	0.000298	0.0029	CbGpPWpGaD
Amiloride—PLAU—AP-1 transcription factor network—CTNNB1—pancreatic cancer	0.000296	0.00288	CbGpPWpGaD
Amiloride—SCNN1D—Transmembrane transport of small molecules—SLC2A2—pancreatic cancer	0.000296	0.00288	CbGpPWpGaD
Amiloride—SCNN1G—Transmembrane transport of small molecules—SLC2A2—pancreatic cancer	0.000296	0.00288	CbGpPWpGaD
Amiloride—SCNN1A—Transmembrane transport of small molecules—SLC2A2—pancreatic cancer	0.000296	0.00288	CbGpPWpGaD
Amiloride—SCNN1B—Transmembrane transport of small molecules—SLC2A2—pancreatic cancer	0.000296	0.00288	CbGpPWpGaD
Amiloride—ASIC1—Transmembrane transport of small molecules—SLC2A2—pancreatic cancer	0.000296	0.00288	CbGpPWpGaD
Amiloride—PLAU—Senescence and Autophagy in Cancer—RB1—pancreatic cancer	0.000291	0.00283	CbGpPWpGaD
Amiloride—PLAU—AP-1 transcription factor network—MMP9—pancreatic cancer	0.00029	0.00283	CbGpPWpGaD
Amiloride—SLC22A4—Transmembrane transport of small molecules—FXYD3—pancreatic cancer	0.00029	0.00282	CbGpPWpGaD
Amiloride—PLAU—AP-1 transcription factor network—PTEN—pancreatic cancer	0.000288	0.00281	CbGpPWpGaD
Amiloride—PLAU—Endochondral Ossification—VEGFA—pancreatic cancer	0.00028	0.00273	CbGpPWpGaD
Amiloride—PLAU—Hemostasis—IFNA5—pancreatic cancer	0.000278	0.00271	CbGpPWpGaD
Amiloride—PLAU—Beta1 integrin cell surface interactions—VEGFA—pancreatic cancer	0.000273	0.00266	CbGpPWpGaD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—PIK3CD—pancreatic cancer	0.000269	0.00262	CbGpPWpGaD
Amiloride—SLC9A1—ErbB1 downstream signaling—PIK3CB—pancreatic cancer	0.000267	0.00261	CbGpPWpGaD
Amiloride—SLC9A1—Regulation of Actin Cytoskeleton—PIK3CG—pancreatic cancer	0.000264	0.00257	CbGpPWpGaD
Amiloride—PLAU—Hemostasis—PPP2R5B—pancreatic cancer	0.000262	0.00256	CbGpPWpGaD
Amiloride—SLC9A1—Regulation of Actin Cytoskeleton—EGF—pancreatic cancer	0.000261	0.00254	CbGpPWpGaD
Amiloride—Hepatic function abnormal—Epirubicin—pancreatic cancer	0.000258	0.00246	CcSEcCtD
Amiloride—Dyspnoea—Sunitinib—pancreatic cancer	0.000258	0.00245	CcSEcCtD
Amiloride—PLAU—Endochondral Ossification—TGFB1—pancreatic cancer	0.000257	0.0025	CbGpPWpGaD
Amiloride—PLAU—Senescence and Autophagy in Cancer—CDKN2A—pancreatic cancer	0.000256	0.00249	CbGpPWpGaD
Amiloride—Cough—Irinotecan—pancreatic cancer	0.000254	0.00242	CcSEcCtD
Amiloride—Dyspepsia—Sunitinib—pancreatic cancer	0.000254	0.00242	CcSEcCtD
Amiloride—Jaundice—Docetaxel—pancreatic cancer	0.000251	0.00239	CcSEcCtD
Amiloride—Decreased appetite—Sunitinib—pancreatic cancer	0.000251	0.00239	CcSEcCtD
Amiloride—PLAU—FGF signaling pathway—PIK3CA—pancreatic cancer	0.00025	0.00244	CbGpPWpGaD
Amiloride—Gastrointestinal disorder—Sunitinib—pancreatic cancer	0.000249	0.00238	CcSEcCtD
Amiloride—Fatigue—Sunitinib—pancreatic cancer	0.000249	0.00237	CcSEcCtD
Amiloride—PLAU—Wnt Signaling Pathway—MYC—pancreatic cancer	0.000248	0.00242	CbGpPWpGaD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—CDKN2A—pancreatic cancer	0.000248	0.00242	CbGpPWpGaD
Amiloride—Cough—Gemcitabine—pancreatic cancer	0.000248	0.00236	CcSEcCtD
Amiloride—Pain—Sunitinib—pancreatic cancer	0.000247	0.00235	CcSEcCtD
Amiloride—Constipation—Sunitinib—pancreatic cancer	0.000247	0.00235	CcSEcCtD
Amiloride—Asthenia—Tamoxifen—pancreatic cancer	0.000242	0.00231	CcSEcCtD
Amiloride—Chest pain—Gemcitabine—pancreatic cancer	0.000242	0.0023	CcSEcCtD
Amiloride—Arthralgia—Gemcitabine—pancreatic cancer	0.000242	0.0023	CcSEcCtD
Amiloride—Confusional state—Irinotecan—pancreatic cancer	0.00024	0.00229	CcSEcCtD
Amiloride—PLAU—AP-1 transcription factor network—MYC—pancreatic cancer	0.00024	0.00233	CbGpPWpGaD
Amiloride—Asthenia—Erlotinib—pancreatic cancer	0.000239	0.00228	CcSEcCtD
Amiloride—PLAU—AP-1 transcription factor network—TGFB1—pancreatic cancer	0.000239	0.00233	CbGpPWpGaD
Amiloride—Hepatic function abnormal—Doxorubicin—pancreatic cancer	0.000239	0.00228	CcSEcCtD
Amiloride—Pruritus—Tamoxifen—pancreatic cancer	0.000239	0.00227	CcSEcCtD
Amiloride—Chest pain—Fluorouracil—pancreatic cancer	0.000238	0.00226	CcSEcCtD
Amiloride—Gastrointestinal pain—Sunitinib—pancreatic cancer	0.000236	0.00225	CcSEcCtD
Amiloride—Pruritus—Erlotinib—pancreatic cancer	0.000236	0.00225	CcSEcCtD
Amiloride—SLC22A4—Transmembrane transport of small molecules—SLC29A1—pancreatic cancer	0.000236	0.0023	CbGpPWpGaD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—PIK3CB—pancreatic cancer	0.000234	0.00228	CbGpPWpGaD
Amiloride—Shock—Irinotecan—pancreatic cancer	0.000234	0.00223	CcSEcCtD
Amiloride—Haemoglobin—Docetaxel—pancreatic cancer	0.000233	0.00222	CcSEcCtD
Amiloride—SLC9A1—Regulation of Actin Cytoskeleton—PIK3CD—pancreatic cancer	0.000232	0.00226	CbGpPWpGaD
Amiloride—PLAU—Senescence and Autophagy in Cancer—CXCL8—pancreatic cancer	0.000232	0.00226	CbGpPWpGaD
Amiloride—PLAU—E2F transcription factor network—MYC—pancreatic cancer	0.000232	0.00226	CbGpPWpGaD
Amiloride—Haemorrhage—Docetaxel—pancreatic cancer	0.000232	0.00221	CcSEcCtD
Amiloride—Diarrhoea—Tamoxifen—pancreatic cancer	0.000231	0.0022	CcSEcCtD
Amiloride—Confusional state—Fluorouracil—pancreatic cancer	0.00023	0.00219	CcSEcCtD
Amiloride—Abdominal pain—Sunitinib—pancreatic cancer	0.000228	0.00218	CcSEcCtD
Amiloride—Diarrhoea—Erlotinib—pancreatic cancer	0.000228	0.00218	CcSEcCtD
Amiloride—SLC9A1—G Protein Signaling Pathways—NRAS—pancreatic cancer	0.000227	0.00221	CbGpPWpGaD
Amiloride—SLC9A1—Endothelins—HRAS—pancreatic cancer	0.000227	0.00221	CbGpPWpGaD
Amiloride—Anorexia—Irinotecan—pancreatic cancer	0.000227	0.00216	CcSEcCtD
Amiloride—Hyponatraemia—Epirubicin—pancreatic cancer	0.000227	0.00216	CcSEcCtD
Amiloride—Pain in extremity—Epirubicin—pancreatic cancer	0.000226	0.00215	CcSEcCtD
Amiloride—Gastrointestinal haemorrhage—Epirubicin—pancreatic cancer	0.000226	0.00215	CcSEcCtD
Amiloride—Visual impairment—Docetaxel—pancreatic cancer	0.000223	0.00213	CcSEcCtD
Amiloride—Dizziness—Tamoxifen—pancreatic cancer	0.000223	0.00212	CcSEcCtD
Amiloride—PLAU—Wnt Signaling Pathway and Pluripotency—CCND1—pancreatic cancer	0.000221	0.00215	CbGpPWpGaD
Amiloride—Anorexia—Gemcitabine—pancreatic cancer	0.000221	0.0021	CcSEcCtD
Amiloride—Dizziness—Erlotinib—pancreatic cancer	0.000221	0.0021	CcSEcCtD
Amiloride—SLC22A2—SLC-mediated transmembrane transport—SLC29A1—pancreatic cancer	0.00022	0.00214	CbGpPWpGaD
Amiloride—PLAU—Wnt Signaling Pathway and Pluripotency—CTNNB1—pancreatic cancer	0.000219	0.00213	CbGpPWpGaD
Amiloride—Anorexia—Fluorouracil—pancreatic cancer	0.000217	0.00207	CcSEcCtD
Amiloride—Insomnia—Irinotecan—pancreatic cancer	0.000215	0.00205	CcSEcCtD
Amiloride—Vomiting—Tamoxifen—pancreatic cancer	0.000214	0.00204	CcSEcCtD
Amiloride—SLC9A1—ErbB1 downstream signaling—SRC—pancreatic cancer	0.000214	0.00209	CbGpPWpGaD
Amiloride—Paraesthesia—Irinotecan—pancreatic cancer	0.000214	0.00204	CcSEcCtD
Amiloride—Rash—Tamoxifen—pancreatic cancer	0.000213	0.00203	CcSEcCtD
Amiloride—Dermatitis—Tamoxifen—pancreatic cancer	0.000212	0.00202	CcSEcCtD
Amiloride—Vomiting—Erlotinib—pancreatic cancer	0.000212	0.00202	CcSEcCtD
Amiloride—Dyspnoea—Irinotecan—pancreatic cancer	0.000212	0.00202	CcSEcCtD
Amiloride—Somnolence—Irinotecan—pancreatic cancer	0.000212	0.00202	CcSEcCtD
Amiloride—Headache—Tamoxifen—pancreatic cancer	0.000211	0.00201	CcSEcCtD
Amiloride—Musculoskeletal discomfort—Gemcitabine—pancreatic cancer	0.000211	0.00201	CcSEcCtD
Amiloride—Rash—Erlotinib—pancreatic cancer	0.00021	0.002	CcSEcCtD
Amiloride—Dermatitis—Erlotinib—pancreatic cancer	0.00021	0.002	CcSEcCtD
Amiloride—Hyponatraemia—Doxorubicin—pancreatic cancer	0.00021	0.002	CcSEcCtD
Amiloride—Insomnia—Gemcitabine—pancreatic cancer	0.00021	0.002	CcSEcCtD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—CCND1—pancreatic cancer	0.00021	0.00204	CbGpPWpGaD
Amiloride—Dyspepsia—Irinotecan—pancreatic cancer	0.000209	0.002	CcSEcCtD
Amiloride—Headache—Erlotinib—pancreatic cancer	0.000209	0.00199	CcSEcCtD
Amiloride—Pain in extremity—Doxorubicin—pancreatic cancer	0.000209	0.00199	CcSEcCtD
Amiloride—Gastrointestinal haemorrhage—Doxorubicin—pancreatic cancer	0.000209	0.00199	CcSEcCtD
Amiloride—PLAU—Senescence and Autophagy in Cancer—PTEN—pancreatic cancer	0.000208	0.00203	CbGpPWpGaD
Amiloride—Paraesthesia—Gemcitabine—pancreatic cancer	0.000208	0.00198	CcSEcCtD
Amiloride—Musculoskeletal discomfort—Fluorouracil—pancreatic cancer	0.000208	0.00198	CcSEcCtD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—CTNNB1—pancreatic cancer	0.000208	0.00202	CbGpPWpGaD
Amiloride—Asthenia—Sunitinib—pancreatic cancer	0.000207	0.00197	CcSEcCtD
Amiloride—Decreased appetite—Irinotecan—pancreatic cancer	0.000207	0.00197	CcSEcCtD
Amiloride—SLC9A1—ErbB1 downstream signaling—STAT3—pancreatic cancer	0.000207	0.00201	CbGpPWpGaD
Amiloride—Dyspnoea—Gemcitabine—pancreatic cancer	0.000207	0.00197	CcSEcCtD
Amiloride—SLC9A1—ErbB1 downstream signaling—NRAS—pancreatic cancer	0.000206	0.00201	CbGpPWpGaD
Amiloride—Orthostatic hypotension—Epirubicin—pancreatic cancer	0.000206	0.00196	CcSEcCtD
Amiloride—Insomnia—Fluorouracil—pancreatic cancer	0.000206	0.00196	CcSEcCtD
Amiloride—Somnolence—Gemcitabine—pancreatic cancer	0.000206	0.00196	CcSEcCtD
Amiloride—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.000205	0.00196	CcSEcCtD
Amiloride—Fatigue—Irinotecan—pancreatic cancer	0.000205	0.00195	CcSEcCtD
Amiloride—SLC22A1—SLC-mediated transmembrane transport—SLC29A1—pancreatic cancer	0.000205	0.00199	CbGpPWpGaD
Amiloride—Paraesthesia—Fluorouracil—pancreatic cancer	0.000205	0.00195	CcSEcCtD
Amiloride—Alopecia—Docetaxel—pancreatic cancer	0.000205	0.00195	CcSEcCtD
Amiloride—PLAU—FGF signaling pathway—AKT1—pancreatic cancer	0.000205	0.00199	CbGpPWpGaD
Amiloride—Pruritus—Sunitinib—pancreatic cancer	0.000204	0.00195	CcSEcCtD
Amiloride—Pain—Irinotecan—pancreatic cancer	0.000203	0.00194	CcSEcCtD
Amiloride—Constipation—Irinotecan—pancreatic cancer	0.000203	0.00194	CcSEcCtD
Amiloride—Dyspnoea—Fluorouracil—pancreatic cancer	0.000203	0.00194	CcSEcCtD
Amiloride—Somnolence—Fluorouracil—pancreatic cancer	0.000203	0.00193	CcSEcCtD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—PTEN—pancreatic cancer	0.000202	0.00197	CbGpPWpGaD
Amiloride—SLC9A1—Regulation of Actin Cytoskeleton—PIK3CB—pancreatic cancer	0.000202	0.00197	CbGpPWpGaD
Amiloride—Decreased appetite—Gemcitabine—pancreatic cancer	0.000201	0.00192	CcSEcCtD
Amiloride—Dyspepsia—Fluorouracil—pancreatic cancer	0.000201	0.00191	CcSEcCtD
Amiloride—SLC9A1—Endothelins—AKT1—pancreatic cancer	0.0002	0.00195	CbGpPWpGaD
Amiloride—Nausea—Tamoxifen—pancreatic cancer	0.0002	0.00191	CcSEcCtD
Amiloride—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.0002	0.00191	CcSEcCtD
Amiloride—Fatigue—Gemcitabine—pancreatic cancer	0.0002	0.0019	CcSEcCtD
Amiloride—Muscular weakness—Epirubicin—pancreatic cancer	0.000199	0.0019	CcSEcCtD
Amiloride—Pain—Gemcitabine—pancreatic cancer	0.000198	0.00189	CcSEcCtD
Amiloride—Constipation—Gemcitabine—pancreatic cancer	0.000198	0.00189	CcSEcCtD
Amiloride—Nausea—Erlotinib—pancreatic cancer	0.000198	0.00189	CcSEcCtD
Amiloride—Decreased appetite—Fluorouracil—pancreatic cancer	0.000198	0.00189	CcSEcCtD
Amiloride—Diarrhoea—Sunitinib—pancreatic cancer	0.000198	0.00188	CcSEcCtD
Amiloride—PLAU—AP-1 transcription factor network—TP53—pancreatic cancer	0.000197	0.00192	CbGpPWpGaD
Amiloride—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.000197	0.00187	CcSEcCtD
Amiloride—Abdominal distension—Epirubicin—pancreatic cancer	0.000196	0.00187	CcSEcCtD
Amiloride—Feeling abnormal—Irinotecan—pancreatic cancer	0.000196	0.00187	CcSEcCtD
Amiloride—SLC9A1—G Protein Signaling Pathways—KRAS—pancreatic cancer	0.000196	0.00191	CbGpPWpGaD
Amiloride—Back pain—Docetaxel—pancreatic cancer	0.000195	0.00186	CcSEcCtD
Amiloride—Pain—Fluorouracil—pancreatic cancer	0.000195	0.00186	CcSEcCtD
Amiloride—SLC9A1—Transmembrane transport of small molecules—SLC2A2—pancreatic cancer	0.000195	0.0019	CbGpPWpGaD
Amiloride—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.000195	0.00185	CcSEcCtD
Amiloride—Muscle spasms—Docetaxel—pancreatic cancer	0.000194	0.00185	CcSEcCtD
Amiloride—PLAU—Senescence and Autophagy in Cancer—SRC—pancreatic cancer	0.000193	0.00188	CbGpPWpGaD
Amiloride—SLC9A1—Disease—ZNRF3—pancreatic cancer	0.000191	0.00186	CbGpPWpGaD
Amiloride—SLC9A1—Disease—PRSS1—pancreatic cancer	0.000191	0.00186	CbGpPWpGaD
Amiloride—Dizziness—Sunitinib—pancreatic cancer	0.000191	0.00182	CcSEcCtD
Amiloride—Feeling abnormal—Gemcitabine—pancreatic cancer	0.000191	0.00182	CcSEcCtD
Amiloride—Orthostatic hypotension—Doxorubicin—pancreatic cancer	0.000191	0.00182	CcSEcCtD
Amiloride—Angina pectoris—Epirubicin—pancreatic cancer	0.00019	0.00181	CcSEcCtD
Amiloride—Abdominal pain—Irinotecan—pancreatic cancer	0.000188	0.00179	CcSEcCtD
Amiloride—SLC9A1—ErbB1 downstream signaling—EGFR—pancreatic cancer	0.000188	0.00183	CbGpPWpGaD
Amiloride—Feeling abnormal—Fluorouracil—pancreatic cancer	0.000188	0.00179	CcSEcCtD
Amiloride—Muscular weakness—Doxorubicin—pancreatic cancer	0.000184	0.00175	CcSEcCtD
Amiloride—Vomiting—Sunitinib—pancreatic cancer	0.000184	0.00175	CcSEcCtD
Amiloride—SLC22A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A2—pancreatic cancer	0.000183	0.00178	CbGpPWpGaD
Amiloride—Neutropenia—Epirubicin—pancreatic cancer	0.000182	0.00174	CcSEcCtD
Amiloride—Dysuria—Epirubicin—pancreatic cancer	0.000182	0.00174	CcSEcCtD
Amiloride—Rash—Sunitinib—pancreatic cancer	0.000182	0.00174	CcSEcCtD
Amiloride—Dermatitis—Sunitinib—pancreatic cancer	0.000182	0.00173	CcSEcCtD
Amiloride—Abdominal distension—Doxorubicin—pancreatic cancer	0.000182	0.00173	CcSEcCtD
Amiloride—Headache—Sunitinib—pancreatic cancer	0.000181	0.00172	CcSEcCtD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—NRAS—pancreatic cancer	0.000181	0.00176	CbGpPWpGaD
Amiloride—Pollakiuria—Epirubicin—pancreatic cancer	0.00018	0.00172	CcSEcCtD
Amiloride—PLAU—Endochondral Ossification—AKT1—pancreatic cancer	0.000179	0.00174	CbGpPWpGaD
Amiloride—Palpitations—Docetaxel—pancreatic cancer	0.000178	0.0017	CcSEcCtD
Amiloride—SLC9A1—ErbB1 downstream signaling—KRAS—pancreatic cancer	0.000177	0.00173	CbGpPWpGaD
Amiloride—PLAU—Wnt Signaling Pathway and Pluripotency—MYC—pancreatic cancer	0.000177	0.00173	CbGpPWpGaD
Amiloride—Cough—Docetaxel—pancreatic cancer	0.000176	0.00168	CcSEcCtD
Amiloride—Angina pectoris—Doxorubicin—pancreatic cancer	0.000176	0.00168	CcSEcCtD
Amiloride—SLC22A4—SLC-mediated transmembrane transport—SLC2A2—pancreatic cancer	0.000175	0.00171	CbGpPWpGaD
Amiloride—PLAU—Senescence and Autophagy in Cancer—TGFB1—pancreatic cancer	0.000173	0.00168	CbGpPWpGaD
Amiloride—SLC9A1—Disease—DTX1—pancreatic cancer	0.000173	0.00168	CbGpPWpGaD
Amiloride—Arthralgia—Docetaxel—pancreatic cancer	0.000172	0.00163	CcSEcCtD
Amiloride—Chest pain—Docetaxel—pancreatic cancer	0.000172	0.00163	CcSEcCtD
Amiloride—Nausea—Sunitinib—pancreatic cancer	0.000172	0.00163	CcSEcCtD
Amiloride—Asthenia—Irinotecan—pancreatic cancer	0.000171	0.00163	CcSEcCtD
Amiloride—SLC22A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A2—pancreatic cancer	0.00017	0.00166	CbGpPWpGaD
Amiloride—Jaundice—Epirubicin—pancreatic cancer	0.00017	0.00162	CcSEcCtD
Amiloride—Dysuria—Doxorubicin—pancreatic cancer	0.000169	0.00161	CcSEcCtD
Amiloride—Neutropenia—Doxorubicin—pancreatic cancer	0.000169	0.00161	CcSEcCtD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—MYC—pancreatic cancer	0.000168	0.00164	CbGpPWpGaD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—TGFB1—pancreatic cancer	0.000168	0.00163	CbGpPWpGaD
Amiloride—Pollakiuria—Doxorubicin—pancreatic cancer	0.000167	0.00159	CcSEcCtD
Amiloride—Asthenia—Gemcitabine—pancreatic cancer	0.000166	0.00158	CcSEcCtD
Amiloride—SLC9A1—G Protein Signaling Pathways—HRAS—pancreatic cancer	0.000166	0.00162	CbGpPWpGaD
Amiloride—Confusional state—Docetaxel—pancreatic cancer	0.000166	0.00158	CcSEcCtD
Amiloride—Pruritus—Gemcitabine—pancreatic cancer	0.000164	0.00156	CcSEcCtD
Amiloride—SLC9A1—ErbB1 downstream signaling—PIK3CA—pancreatic cancer	0.000163	0.00159	CbGpPWpGaD
Amiloride—Diarrhoea—Irinotecan—pancreatic cancer	0.000163	0.00155	CcSEcCtD
Amiloride—Shock—Docetaxel—pancreatic cancer	0.000162	0.00154	CcSEcCtD
Amiloride—Pruritus—Fluorouracil—pancreatic cancer	0.000161	0.00154	CcSEcCtD
Amiloride—SLC9A1—Metabolism—PRSS1—pancreatic cancer	0.00016	0.00156	CbGpPWpGaD
Amiloride—Bradycardia—Epirubicin—pancreatic cancer	0.000159	0.00151	CcSEcCtD
Amiloride—Diarrhoea—Gemcitabine—pancreatic cancer	0.000159	0.00151	CcSEcCtD
Amiloride—Dizziness—Irinotecan—pancreatic cancer	0.000157	0.0015	CcSEcCtD
Amiloride—PLAU—Hemostasis—CD44—pancreatic cancer	0.000157	0.00153	CbGpPWpGaD
Amiloride—Haemoglobin—Epirubicin—pancreatic cancer	0.000157	0.0015	CcSEcCtD
Amiloride—Jaundice—Doxorubicin—pancreatic cancer	0.000157	0.00149	CcSEcCtD
Amiloride—Anorexia—Docetaxel—pancreatic cancer	0.000157	0.00149	CcSEcCtD
Amiloride—Haemorrhage—Epirubicin—pancreatic cancer	0.000156	0.00149	CcSEcCtD
Amiloride—Diarrhoea—Fluorouracil—pancreatic cancer	0.000156	0.00149	CcSEcCtD
Amiloride—SLC9A1—Regulation of Actin Cytoskeleton—NRAS—pancreatic cancer	0.000156	0.00152	CbGpPWpGaD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—KRAS—pancreatic cancer	0.000155	0.00151	CbGpPWpGaD
Amiloride—PLAU—Hemostasis—IFNA1—pancreatic cancer	0.000152	0.00148	CbGpPWpGaD
Amiloride—Vomiting—Irinotecan—pancreatic cancer	0.000151	0.00144	CcSEcCtD
Amiloride—SLC9A1—ErbB1 downstream signaling—HRAS—pancreatic cancer	0.000151	0.00147	CbGpPWpGaD
Amiloride—Dizziness—Fluorouracil—pancreatic cancer	0.000151	0.00144	CcSEcCtD
Amiloride—Visual impairment—Epirubicin—pancreatic cancer	0.00015	0.00143	CcSEcCtD
Amiloride—Rash—Irinotecan—pancreatic cancer	0.00015	0.00143	CcSEcCtD
Amiloride—Dermatitis—Irinotecan—pancreatic cancer	0.00015	0.00143	CcSEcCtD
Amiloride—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.00015	0.00143	CcSEcCtD
Amiloride—Headache—Irinotecan—pancreatic cancer	0.000149	0.00142	CcSEcCtD
Amiloride—Insomnia—Docetaxel—pancreatic cancer	0.000149	0.00142	CcSEcCtD
Amiloride—Paraesthesia—Docetaxel—pancreatic cancer	0.000148	0.00141	CcSEcCtD
Amiloride—Vomiting—Gemcitabine—pancreatic cancer	0.000147	0.0014	CcSEcCtD
Amiloride—Bradycardia—Doxorubicin—pancreatic cancer	0.000147	0.0014	CcSEcCtD
Amiloride—Dyspnoea—Docetaxel—pancreatic cancer	0.000147	0.0014	CcSEcCtD
Amiloride—Somnolence—Docetaxel—pancreatic cancer	0.000146	0.00139	CcSEcCtD
Amiloride—Rash—Gemcitabine—pancreatic cancer	0.000146	0.00139	CcSEcCtD
Amiloride—Dermatitis—Gemcitabine—pancreatic cancer	0.000146	0.00139	CcSEcCtD
Amiloride—PLAU—Wnt Signaling Pathway and Pluripotency—TP53—pancreatic cancer	0.000146	0.00142	CbGpPWpGaD
Amiloride—Tinnitus—Epirubicin—pancreatic cancer	0.000146	0.00139	CcSEcCtD
Amiloride—Haemoglobin—Doxorubicin—pancreatic cancer	0.000145	0.00138	CcSEcCtD
Amiloride—Headache—Gemcitabine—pancreatic cancer	0.000145	0.00138	CcSEcCtD
Amiloride—Vomiting—Fluorouracil—pancreatic cancer	0.000145	0.00138	CcSEcCtD
Amiloride—SLC9A1—Disease—DTX4—pancreatic cancer	0.000145	0.00141	CbGpPWpGaD
Amiloride—Dyspepsia—Docetaxel—pancreatic cancer	0.000145	0.00138	CcSEcCtD
Amiloride—Haemorrhage—Doxorubicin—pancreatic cancer	0.000144	0.00138	CcSEcCtD
Amiloride—Rash—Fluorouracil—pancreatic cancer	0.000144	0.00137	CcSEcCtD
Amiloride—Dermatitis—Fluorouracil—pancreatic cancer	0.000144	0.00137	CcSEcCtD
Amiloride—Decreased appetite—Docetaxel—pancreatic cancer	0.000143	0.00136	CcSEcCtD
Amiloride—Headache—Fluorouracil—pancreatic cancer	0.000143	0.00136	CcSEcCtD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—PIK3CA—pancreatic cancer	0.000143	0.00139	CbGpPWpGaD
Amiloride—PLAU—Senescence and Autophagy in Cancer—TP53—pancreatic cancer	0.000142	0.00139	CbGpPWpGaD
Amiloride—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000142	0.00135	CcSEcCtD
Amiloride—SLC9A1—Regulation of Actin Cytoskeleton—EGFR—pancreatic cancer	0.000142	0.00138	CbGpPWpGaD
Amiloride—Fatigue—Docetaxel—pancreatic cancer	0.000142	0.00135	CcSEcCtD
Amiloride—PLAU—Hemostasis—IFNA2—pancreatic cancer	0.000142	0.00138	CbGpPWpGaD
Amiloride—Nausea—Irinotecan—pancreatic cancer	0.000141	0.00135	CcSEcCtD
Amiloride—SLC9A1—Disease—PPP2R5B—pancreatic cancer	0.000141	0.00137	CbGpPWpGaD
Amiloride—Constipation—Docetaxel—pancreatic cancer	0.000141	0.00134	CcSEcCtD
Amiloride—Pain—Docetaxel—pancreatic cancer	0.000141	0.00134	CcSEcCtD
Amiloride—Visual impairment—Doxorubicin—pancreatic cancer	0.000139	0.00133	CcSEcCtD
Amiloride—SLC9A1—Metabolism—ARG2—pancreatic cancer	0.000139	0.00135	CbGpPWpGaD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—TP53—pancreatic cancer	0.000138	0.00135	CbGpPWpGaD
Amiloride—Alopecia—Epirubicin—pancreatic cancer	0.000138	0.00131	CcSEcCtD
Amiloride—Nausea—Gemcitabine—pancreatic cancer	0.000138	0.00131	CcSEcCtD
Amiloride—SLC22A2—Transmembrane transport of small molecules—FXYD3—pancreatic cancer	0.000137	0.00133	CbGpPWpGaD
Amiloride—PLAU—Senescence and Autophagy in Cancer—HRAS—pancreatic cancer	0.000136	0.00133	CbGpPWpGaD
Amiloride—SLC9A1—Disease—HEY2—pancreatic cancer	0.000136	0.00132	CbGpPWpGaD
Amiloride—Feeling abnormal—Docetaxel—pancreatic cancer	0.000136	0.00129	CcSEcCtD
Amiloride—Nausea—Fluorouracil—pancreatic cancer	0.000135	0.00129	CcSEcCtD
Amiloride—Tinnitus—Doxorubicin—pancreatic cancer	0.000135	0.00128	CcSEcCtD
Amiloride—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000135	0.00128	CcSEcCtD
Amiloride—SLC9A1—Regulation of Actin Cytoskeleton—KRAS—pancreatic cancer	0.000134	0.00131	CbGpPWpGaD
Amiloride—Flatulence—Epirubicin—pancreatic cancer	0.000134	0.00128	CcSEcCtD
Amiloride—Tension—Epirubicin—pancreatic cancer	0.000133	0.00127	CcSEcCtD
Amiloride—SLC9A1—ErbB1 downstream signaling—AKT1—pancreatic cancer	0.000133	0.0013	CbGpPWpGaD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—HRAS—pancreatic cancer	0.000132	0.00129	CbGpPWpGaD
Amiloride—Nervousness—Epirubicin—pancreatic cancer	0.000132	0.00126	CcSEcCtD
Amiloride—Back pain—Epirubicin—pancreatic cancer	0.000131	0.00125	CcSEcCtD
Amiloride—Muscle spasms—Epirubicin—pancreatic cancer	0.000131	0.00125	CcSEcCtD
Amiloride—Abdominal pain—Docetaxel—pancreatic cancer	0.00013	0.00124	CcSEcCtD
Amiloride—Alopecia—Doxorubicin—pancreatic cancer	0.000128	0.00122	CcSEcCtD
Amiloride—SLC22A1—Transmembrane transport of small molecules—FXYD3—pancreatic cancer	0.000128	0.00124	CbGpPWpGaD
Amiloride—SLC9A1—Disease—HEY1—pancreatic cancer	0.000126	0.00122	CbGpPWpGaD
Amiloride—Flatulence—Doxorubicin—pancreatic cancer	0.000124	0.00118	CcSEcCtD
Amiloride—Tension—Doxorubicin—pancreatic cancer	0.000123	0.00118	CcSEcCtD
Amiloride—SLC9A1—Regulation of Actin Cytoskeleton—PIK3CA—pancreatic cancer	0.000123	0.0012	CbGpPWpGaD
Amiloride—Nervousness—Doxorubicin—pancreatic cancer	0.000122	0.00116	CcSEcCtD
Amiloride—Vertigo—Epirubicin—pancreatic cancer	0.000122	0.00116	CcSEcCtD
Amiloride—Back pain—Doxorubicin—pancreatic cancer	0.000122	0.00116	CcSEcCtD
Amiloride—SLC9A1—Metabolism—TYMP—pancreatic cancer	0.000121	0.00118	CbGpPWpGaD
Amiloride—Muscle spasms—Doxorubicin—pancreatic cancer	0.000121	0.00115	CcSEcCtD
Amiloride—Palpitations—Epirubicin—pancreatic cancer	0.00012	0.00114	CcSEcCtD
Amiloride—Cough—Epirubicin—pancreatic cancer	0.000119	0.00113	CcSEcCtD
Amiloride—Asthenia—Docetaxel—pancreatic cancer	0.000118	0.00112	CcSEcCtD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—AKT1—pancreatic cancer	0.000117	0.00114	CbGpPWpGaD
Amiloride—Pruritus—Docetaxel—pancreatic cancer	0.000116	0.00111	CcSEcCtD
Amiloride—Arthralgia—Epirubicin—pancreatic cancer	0.000116	0.0011	CcSEcCtD
Amiloride—Chest pain—Epirubicin—pancreatic cancer	0.000116	0.0011	CcSEcCtD
Amiloride—Vertigo—Doxorubicin—pancreatic cancer	0.000113	0.00108	CcSEcCtD
Amiloride—Diarrhoea—Docetaxel—pancreatic cancer	0.000113	0.00107	CcSEcCtD
Amiloride—Confusional state—Epirubicin—pancreatic cancer	0.000112	0.00107	CcSEcCtD
Amiloride—SLC22A2—Transmembrane transport of small molecules—SLC29A1—pancreatic cancer	0.000112	0.00109	CbGpPWpGaD
Amiloride—SLC9A1—Disease—JAG2—pancreatic cancer	0.000111	0.00108	CbGpPWpGaD
Amiloride—Palpitations—Doxorubicin—pancreatic cancer	0.000111	0.00106	CcSEcCtD
Amiloride—Cough—Doxorubicin—pancreatic cancer	0.00011	0.00105	CcSEcCtD
Amiloride—SLC9A1—Disease—MEN1—pancreatic cancer	0.00011	0.00107	CbGpPWpGaD
Amiloride—Shock—Epirubicin—pancreatic cancer	0.000109	0.00104	CcSEcCtD
Amiloride—SLC9A1—Disease—SLC2A2—pancreatic cancer	0.000109	0.00106	CbGpPWpGaD
Amiloride—Dizziness—Docetaxel—pancreatic cancer	0.000109	0.00104	CcSEcCtD
Amiloride—Chest pain—Doxorubicin—pancreatic cancer	0.000107	0.00102	CcSEcCtD
Amiloride—Arthralgia—Doxorubicin—pancreatic cancer	0.000107	0.00102	CcSEcCtD
Amiloride—Anorexia—Epirubicin—pancreatic cancer	0.000106	0.00101	CcSEcCtD
Amiloride—SLC9A1—Disease—SHH—pancreatic cancer	0.000105	0.00102	CbGpPWpGaD
Amiloride—Vomiting—Docetaxel—pancreatic cancer	0.000105	0.000996	CcSEcCtD
Amiloride—SLC22A1—Transmembrane transport of small molecules—SLC29A1—pancreatic cancer	0.000104	0.00101	CbGpPWpGaD
Amiloride—Rash—Docetaxel—pancreatic cancer	0.000104	0.000988	CcSEcCtD
Amiloride—Dermatitis—Docetaxel—pancreatic cancer	0.000104	0.000987	CcSEcCtD
Amiloride—Confusional state—Doxorubicin—pancreatic cancer	0.000104	0.000986	CcSEcCtD
Amiloride—SLC9A1—Disease—IAPP—pancreatic cancer	0.000103	0.00101	CbGpPWpGaD
Amiloride—Headache—Docetaxel—pancreatic cancer	0.000103	0.000982	CcSEcCtD
Amiloride—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.000101	0.000963	CcSEcCtD
Amiloride—Shock—Doxorubicin—pancreatic cancer	0.000101	0.000962	CcSEcCtD
Amiloride—Insomnia—Epirubicin—pancreatic cancer	0.0001	0.000956	CcSEcCtD
Amiloride—Paraesthesia—Epirubicin—pancreatic cancer	9.96e-05	0.000949	CcSEcCtD
Amiloride—SLC9A1—Disease—HSPA1B—pancreatic cancer	9.93e-05	0.000967	CbGpPWpGaD
Amiloride—Dyspnoea—Epirubicin—pancreatic cancer	9.89e-05	0.000942	CcSEcCtD
Amiloride—Somnolence—Epirubicin—pancreatic cancer	9.86e-05	0.00094	CcSEcCtD
Amiloride—Anorexia—Doxorubicin—pancreatic cancer	9.79e-05	0.000932	CcSEcCtD
Amiloride—SLC9A1—Metabolism—GLP1R—pancreatic cancer	9.78e-05	0.000952	CbGpPWpGaD
Amiloride—Nausea—Docetaxel—pancreatic cancer	9.77e-05	0.000931	CcSEcCtD
Amiloride—Dyspepsia—Epirubicin—pancreatic cancer	9.77e-05	0.00093	CcSEcCtD
Amiloride—Decreased appetite—Epirubicin—pancreatic cancer	9.64e-05	0.000919	CcSEcCtD
Amiloride—SLC9A1—Metabolism—DPYD—pancreatic cancer	9.62e-05	0.000937	CbGpPWpGaD
Amiloride—Gastrointestinal disorder—Epirubicin—pancreatic cancer	9.58e-05	0.000913	CcSEcCtD
Amiloride—Fatigue—Epirubicin—pancreatic cancer	9.57e-05	0.000911	CcSEcCtD
Amiloride—Pain—Epirubicin—pancreatic cancer	9.49e-05	0.000904	CcSEcCtD
Amiloride—Constipation—Epirubicin—pancreatic cancer	9.49e-05	0.000904	CcSEcCtD
Amiloride—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	9.35e-05	0.000891	CcSEcCtD
Amiloride—Insomnia—Doxorubicin—pancreatic cancer	9.28e-05	0.000885	CcSEcCtD
Amiloride—Paraesthesia—Doxorubicin—pancreatic cancer	9.22e-05	0.000878	CcSEcCtD
Amiloride—Dyspnoea—Doxorubicin—pancreatic cancer	9.15e-05	0.000872	CcSEcCtD
Amiloride—Feeling abnormal—Epirubicin—pancreatic cancer	9.14e-05	0.000871	CcSEcCtD
Amiloride—SLC9A1—Metabolism—SLC2A2—pancreatic cancer	9.13e-05	0.000889	CbGpPWpGaD
Amiloride—Somnolence—Doxorubicin—pancreatic cancer	9.13e-05	0.000869	CcSEcCtD
Amiloride—Gastrointestinal pain—Epirubicin—pancreatic cancer	9.07e-05	0.000864	CcSEcCtD
Amiloride—Dyspepsia—Doxorubicin—pancreatic cancer	9.04e-05	0.000861	CcSEcCtD
Amiloride—PLAU—Hemostasis—PIK3CG—pancreatic cancer	8.95e-05	0.000872	CbGpPWpGaD
Amiloride—Decreased appetite—Doxorubicin—pancreatic cancer	8.92e-05	0.00085	CcSEcCtD
Amiloride—SLC22A4—Transmembrane transport of small molecules—SLC2A2—pancreatic cancer	8.92e-05	0.000869	CbGpPWpGaD
Amiloride—SLC9A1—Disease—JAG1—pancreatic cancer	8.88e-05	0.000865	CbGpPWpGaD
Amiloride—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	8.86e-05	0.000844	CcSEcCtD
Amiloride—Fatigue—Doxorubicin—pancreatic cancer	8.85e-05	0.000843	CcSEcCtD
Amiloride—PLAU—Hemostasis—EGF—pancreatic cancer	8.85e-05	0.000862	CbGpPWpGaD
Amiloride—Pain—Doxorubicin—pancreatic cancer	8.78e-05	0.000836	CcSEcCtD
Amiloride—Constipation—Doxorubicin—pancreatic cancer	8.78e-05	0.000836	CcSEcCtD
Amiloride—Abdominal pain—Epirubicin—pancreatic cancer	8.77e-05	0.000836	CcSEcCtD
Amiloride—Feeling abnormal—Doxorubicin—pancreatic cancer	8.46e-05	0.000806	CcSEcCtD
Amiloride—SLC9A1—Disease—CD44—pancreatic cancer	8.44e-05	0.000822	CbGpPWpGaD
Amiloride—Gastrointestinal pain—Doxorubicin—pancreatic cancer	8.39e-05	0.0008	CcSEcCtD
Amiloride—SLC9A1—Disease—HSPA1A—pancreatic cancer	8.38e-05	0.000816	CbGpPWpGaD
Amiloride—SLC22A2—SLC-mediated transmembrane transport—SLC2A2—pancreatic cancer	8.3e-05	0.000808	CbGpPWpGaD
Amiloride—Abdominal pain—Doxorubicin—pancreatic cancer	8.12e-05	0.000773	CcSEcCtD
Amiloride—Asthenia—Epirubicin—pancreatic cancer	7.96e-05	0.000758	CcSEcCtD
Amiloride—PLAU—Hemostasis—PIK3CD—pancreatic cancer	7.87e-05	0.000766	CbGpPWpGaD
Amiloride—Pruritus—Epirubicin—pancreatic cancer	7.85e-05	0.000748	CcSEcCtD
Amiloride—SLC22A1—SLC-mediated transmembrane transport—SLC2A2—pancreatic cancer	7.74e-05	0.000754	CbGpPWpGaD
Amiloride—Diarrhoea—Epirubicin—pancreatic cancer	7.59e-05	0.000723	CcSEcCtD
Amiloride—Asthenia—Doxorubicin—pancreatic cancer	7.37e-05	0.000702	CcSEcCtD
Amiloride—Dizziness—Epirubicin—pancreatic cancer	7.34e-05	0.000699	CcSEcCtD
Amiloride—Pruritus—Doxorubicin—pancreatic cancer	7.26e-05	0.000692	CcSEcCtD
Amiloride—SLC9A1—Metabolism—CD44—pancreatic cancer	7.07e-05	0.000688	CbGpPWpGaD
Amiloride—Vomiting—Epirubicin—pancreatic cancer	7.05e-05	0.000672	CcSEcCtD
Amiloride—Diarrhoea—Doxorubicin—pancreatic cancer	7.02e-05	0.000669	CcSEcCtD
Amiloride—Rash—Epirubicin—pancreatic cancer	7e-05	0.000666	CcSEcCtD
Amiloride—Dermatitis—Epirubicin—pancreatic cancer	6.99e-05	0.000666	CcSEcCtD
Amiloride—Headache—Epirubicin—pancreatic cancer	6.95e-05	0.000662	CcSEcCtD
Amiloride—PLAU—Hemostasis—PIK3CB—pancreatic cancer	6.86e-05	0.000668	CbGpPWpGaD
Amiloride—Dizziness—Doxorubicin—pancreatic cancer	6.79e-05	0.000647	CcSEcCtD
Amiloride—SLC9A1—Metabolism—GCG—pancreatic cancer	6.78e-05	0.00066	CbGpPWpGaD
Amiloride—SLC9A1—Disease—SMAD4—pancreatic cancer	6.66e-05	0.000649	CbGpPWpGaD
Amiloride—Nausea—Epirubicin—pancreatic cancer	6.59e-05	0.000628	CcSEcCtD
Amiloride—Vomiting—Doxorubicin—pancreatic cancer	6.53e-05	0.000622	CcSEcCtD
Amiloride—SLC9A1—Disease—HES1—pancreatic cancer	6.51e-05	0.000634	CbGpPWpGaD
Amiloride—Rash—Doxorubicin—pancreatic cancer	6.47e-05	0.000617	CcSEcCtD
Amiloride—Dermatitis—Doxorubicin—pancreatic cancer	6.47e-05	0.000616	CcSEcCtD
Amiloride—Headache—Doxorubicin—pancreatic cancer	6.43e-05	0.000613	CcSEcCtD
Amiloride—SLC9A1—Metabolism—STK11—pancreatic cancer	6.37e-05	0.000621	CbGpPWpGaD
Amiloride—Nausea—Doxorubicin—pancreatic cancer	6.1e-05	0.000581	CcSEcCtD
Amiloride—SLC9A1—Disease—TERT—pancreatic cancer	5.7e-05	0.000555	CbGpPWpGaD
Amiloride—PLAU—Hemostasis—SRC—pancreatic cancer	5.49e-05	0.000535	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—TYMS—pancreatic cancer	5.48e-05	0.000534	CbGpPWpGaD
Amiloride—SLC9A1—Disease—HIF1A—pancreatic cancer	5.45e-05	0.000531	CbGpPWpGaD
Amiloride—SLC9A1—Disease—TSC2—pancreatic cancer	5.44e-05	0.00053	CbGpPWpGaD
Amiloride—PLAU—Hemostasis—VEGFA—pancreatic cancer	5.35e-05	0.000521	CbGpPWpGaD
Amiloride—SLC9A1—Disease—APOE—pancreatic cancer	5.32e-05	0.000518	CbGpPWpGaD
Amiloride—PLAU—Hemostasis—NRAS—pancreatic cancer	5.29e-05	0.000515	CbGpPWpGaD
Amiloride—PLAU—Hemostasis—TGFB1—pancreatic cancer	4.91e-05	0.000478	CbGpPWpGaD
Amiloride—SLC9A1—Disease—NOTCH1—pancreatic cancer	4.91e-05	0.000478	CbGpPWpGaD
Amiloride—SLC9A1—Disease—EGF—pancreatic cancer	4.75e-05	0.000462	CbGpPWpGaD
Amiloride—PLAU—Hemostasis—KRAS—pancreatic cancer	4.55e-05	0.000443	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—APOE—pancreatic cancer	4.46e-05	0.000434	CbGpPWpGaD
Amiloride—SLC9A1—Disease—PIK3CD—pancreatic cancer	4.22e-05	0.000411	CbGpPWpGaD
Amiloride—SLC22A2—Transmembrane transport of small molecules—SLC2A2—pancreatic cancer	4.22e-05	0.000411	CbGpPWpGaD
Amiloride—PLAU—Hemostasis—PIK3CA—pancreatic cancer	4.18e-05	0.000407	CbGpPWpGaD
Amiloride—PLAU—Hemostasis—TP53—pancreatic cancer	4.04e-05	0.000394	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—PIK3CG—pancreatic cancer	4.02e-05	0.000392	CbGpPWpGaD
Amiloride—SLC22A1—Transmembrane transport of small molecules—SLC2A2—pancreatic cancer	3.93e-05	0.000383	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—PPARG—pancreatic cancer	3.88e-05	0.000378	CbGpPWpGaD
Amiloride—PLAU—Hemostasis—HRAS—pancreatic cancer	3.87e-05	0.000377	CbGpPWpGaD
Amiloride—SLC9A1—Disease—PIK3CB—pancreatic cancer	3.68e-05	0.000358	CbGpPWpGaD
Amiloride—SLC9A1—Disease—PTGS2—pancreatic cancer	3.65e-05	0.000355	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—PIK3CD—pancreatic cancer	3.54e-05	0.000344	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—PRSS1—pancreatic cancer	3.46e-05	0.000337	CbGpPWpGaD
Amiloride—PLAU—Hemostasis—AKT1—pancreatic cancer	3.41e-05	0.000333	CbGpPWpGaD
Amiloride—SLC9A1—Disease—CTNNB1—pancreatic cancer	3.26e-05	0.000318	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—PRSS1—pancreatic cancer	3.23e-05	0.000314	CbGpPWpGaD
Amiloride—SLC9A1—Disease—PTEN—pancreatic cancer	3.18e-05	0.00031	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—PIK3CB—pancreatic cancer	3.08e-05	0.0003	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—PTGS2—pancreatic cancer	3.05e-05	0.000297	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—ARG2—pancreatic cancer	3e-05	0.000293	CbGpPWpGaD
Amiloride—SLC9A1—Disease—SRC—pancreatic cancer	2.95e-05	0.000287	CbGpPWpGaD
Amiloride—SLC9A1—Disease—STAT3—pancreatic cancer	2.84e-05	0.000277	CbGpPWpGaD
Amiloride—SLC9A1—Disease—NRAS—pancreatic cancer	2.84e-05	0.000276	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—ARG2—pancreatic cancer	2.8e-05	0.000273	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—PTEN—pancreatic cancer	2.66e-05	0.000259	CbGpPWpGaD
Amiloride—SLC9A1—Disease—MYC—pancreatic cancer	2.64e-05	0.000257	CbGpPWpGaD
Amiloride—SLC9A1—Disease—TGFB1—pancreatic cancer	2.64e-05	0.000257	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—TYMP—pancreatic cancer	2.62e-05	0.000256	CbGpPWpGaD
Amiloride—SLC9A1—Disease—EGFR—pancreatic cancer	2.58e-05	0.000252	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—TYMP—pancreatic cancer	2.45e-05	0.000238	CbGpPWpGaD
Amiloride—SLC9A1—Disease—KRAS—pancreatic cancer	2.44e-05	0.000238	CbGpPWpGaD
Amiloride—SLC9A1—Disease—PIK3CA—pancreatic cancer	2.24e-05	0.000219	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—GLP1R—pancreatic cancer	2.12e-05	0.000206	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—DPYD—pancreatic cancer	2.08e-05	0.000203	CbGpPWpGaD
Amiloride—SLC9A1—Disease—HRAS—pancreatic cancer	2.08e-05	0.000202	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—SLC2A2—pancreatic cancer	1.98e-05	0.000192	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—GLP1R—pancreatic cancer	1.97e-05	0.000192	CbGpPWpGaD
Amiloride—SLC22A2—Transmission across Chemical Synapses—HRAS—pancreatic cancer	1.95e-05	0.00019	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—DPYD—pancreatic cancer	1.94e-05	0.000189	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—PIK3CA—pancreatic cancer	1.88e-05	0.000183	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—SLC2A2—pancreatic cancer	1.84e-05	0.000179	CbGpPWpGaD
Amiloride—SLC9A1—Disease—AKT1—pancreatic cancer	1.83e-05	0.000179	CbGpPWpGaD
Amiloride—SLC22A1—Transmission across Chemical Synapses—HRAS—pancreatic cancer	1.82e-05	0.000177	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—AKT1—pancreatic cancer	1.53e-05	0.00015	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—CD44—pancreatic cancer	1.53e-05	0.000149	CbGpPWpGaD
Amiloride—SLC22A2—Neuronal System—HRAS—pancreatic cancer	1.49e-05	0.000146	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—GCG—pancreatic cancer	1.47e-05	0.000143	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—CD44—pancreatic cancer	1.43e-05	0.000139	CbGpPWpGaD
Amiloride—SLC22A1—Neuronal System—HRAS—pancreatic cancer	1.39e-05	0.000136	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—STK11—pancreatic cancer	1.38e-05	0.000134	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—GCG—pancreatic cancer	1.37e-05	0.000133	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—STK11—pancreatic cancer	1.29e-05	0.000125	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—TYMS—pancreatic cancer	1.19e-05	0.000116	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—TYMS—pancreatic cancer	1.11e-05	0.000108	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—APOE—pancreatic cancer	9.65e-06	9.4e-05	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—APOE—pancreatic cancer	8.99e-06	8.76e-05	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—PIK3CG—pancreatic cancer	8.71e-06	8.48e-05	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—PPARG—pancreatic cancer	8.4e-06	8.18e-05	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—PIK3CG—pancreatic cancer	8.11e-06	7.9e-05	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—PPARG—pancreatic cancer	7.83e-06	7.63e-05	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—PIK3CD—pancreatic cancer	7.65e-06	7.46e-05	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—PIK3CD—pancreatic cancer	7.13e-06	6.95e-05	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—PIK3CB—pancreatic cancer	6.67e-06	6.5e-05	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—PTGS2—pancreatic cancer	6.61e-06	6.44e-05	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—PIK3CB—pancreatic cancer	6.22e-06	6.06e-05	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—PTGS2—pancreatic cancer	6.16e-06	6e-05	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—PTEN—pancreatic cancer	5.76e-06	5.62e-05	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—PTEN—pancreatic cancer	5.37e-06	5.23e-05	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—PIK3CA—pancreatic cancer	4.07e-06	3.96e-05	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—PIK3CA—pancreatic cancer	3.79e-06	3.69e-05	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—AKT1—pancreatic cancer	3.32e-06	3.24e-05	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—AKT1—pancreatic cancer	3.1e-06	3.02e-05	CbGpPWpGaD
